1. Home
  2. GPCR vs PHAR Comparison

GPCR vs PHAR Comparison

Compare GPCR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$68.72

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$18.61

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPCR
PHAR
Founded
2016
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
GPCR
PHAR
Price
$68.72
$18.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
2
Target Price
$97.90
$38.00
AVG Volume (30 Days)
1.2M
28.7K
Earning Date
02-26-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.00
Revenue
N/A
$362,274,000.00
Revenue This Year
N/A
$25.19
Revenue Next Year
N/A
$4.47
P/E Ratio
N/A
$3,363.09
Revenue Growth
N/A
26.78
52 Week Low
$13.22
$7.50
52 Week High
$94.90
$18.82

Technical Indicators

Market Signals
Indicator
GPCR
PHAR
Relative Strength Index (RSI) 64.14 61.38
Support Level $61.99 $16.55
Resistance Level $70.40 $17.37
Average True Range (ATR) 4.03 0.73
MACD -1.08 0.05
Stochastic Oscillator 76.21 92.27

Price Performance

Historical Comparison
GPCR
PHAR

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: